Terumo Invests 26 Million Euro in New Production Lines for its Belgian Facility

July 8, 2019

Leuven, Belgium - July 8, 2019 - Terumo Corporation (TSE: 4543), a leading global medical device manufacturer, today announced an investment of 26 million euro in the production facility of Terumo Europe in Leuven (Belgium), where Terumo produces and assembles medical devices. Terumo extends its production capacity at Terumo Europe to meet the growing demand for Terumo products. The new production lines will be operational within two to three years. Terumo Europe employs approximately 1,300 people in the EMEA region.

At the site in Leuven, Terumo produces and assembles medical devices in two production entities.
'For the Alliance division, we will extend our capacity in moulding. We will increase the number of needle assembly lines and we are investing in a flexible assembly line that will allow us to customize production for our customers. For our Interventional Systems division, we will further automate production processes in assembly and packaging', said Henk Houf, Chief Operations Officer of Terumo Europe.

'We are excited that Terumo invests in the production site in Leuven. We believe this investment will accelerate the growth of these two divisions, which will drive the overall Terumo growth in mid- to long-term', said Nori Kunimoto, CEO Terumo Europe.

Terumo Europe

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US$6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index. www.terumo.com

About Terumo Europe

Terumo Europe is a core player in the EMEA healthcare market. Terumo Europe produces, distributes, markets and sells a vast range of medical devices across the EMEA region. As a strong actor of Terumo Corporation, it conducts business locally while pursuing a unified EMEA strategy. The EMEA headquarters and production facilities are based in Leuven (Belgium). The European Distribution Center is based in Genk (Belgium). In addition, we have a production facility in Liverpool (UK) and sales and marketing offices across the EMEA region. Terumo EMEA employs approximately 1,300 Associates. www.terumo-europe.com

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

Print
T
O
P